Advanced Basal Cell Carcinoma Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2016 - 2024

Advanced Basal Cell Carcinoma Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2016 - 2024

  • Transparency Market Research
  • Ongoing
  • Healthcare

Report Description

Advance basal cell carcinoma is abnormal, uncontrolled growth or lesions which appear on the skin, they arise from basal cells of the skin which are found on the inner most layer epidermis. They look like open sores, pink growths, red patches or scars which are caused due to cumulative and intense exposure to the sun. Basal cell carcinoma generally does not spread beyond the original site of the tumor, they mostly affect the head, face scalp, hand and the neck areas but spread to other parts and become malignant if not diagnosed.

Basal cell carcinoma is the most common form of skin cancer which accounts for nearly 80% of all cases, if not treated may get into the advance stage. Basal cell carcinoma which infiltrates below the skin or vital organ is difficult to treat surgically. It is commonly found in elderly and fair skinned individuals. Treatment of advance basal cell carcinoma is carried out with surgical, destructive and topical therapeutic treatments. Although if not treated properly or neglected it may become aggressive or recurrent basal cell carcinoma may progress to an advanced state. The characteristics of a tumor becoming advance basal cell carcinoma may differ. The major challenges in treating advance basal cell carcinoma include its size, location, invasiveness and extent. It comprises of non-melanoma skin cells as compared to other malignancies. Individuals suffering from advance basal cell carcinoma fall under two categories, one who have advance basal cell carcinoma due to delay in accessing medical treatment and with whom basal cell carcinoma reoccur after treatment.

The treatment for advance basal cell carcinoma is quite complicated as both patients and tumor characteristics have to be taken into consideration before starting the treatment. Generally, more than one therapeutic methodology has to be taken into account for the treatment. The mortality rate for basal cell carcinoma is low as compared to other forms of malignant tumors as these rarely become malignant, these tumors are generally curable but sometimes due to reoccurrence it is hard to completely get rid.

There are many different ways to prevent basal cell carcinoma, such as by avoiding skin exposure to direct sunlight, this can be avoided by using high factor sunscreen to exposed skin if outdoors. Cases which are associated with high cost and recovery time the use of radiation therapy or hedgehog inhibitor therapy may be taken into consideration. In some cases where surgery may not be sufficient alternative medication is used which could be topical, oral or hedgehog inhibitors may be taken into consideration. In recent times newer and more effective therapeutics have been developed which include inhibitors which block the Hedgehog pathway which stops the reoccurrence of advance basal cell carcinoma. These new therapeutics would help in extending the lifespan of people who have metastatic advance basal cell carcinoma. Advance basal cell carcinoma are sometime difficult to treat and can become life threatening this is mainly due to reoccurrence rate and progressiveness of the disease. Therefore it requires constant monitoring. The American Cancer Society strongly recommends dermatologic checkup in every three years for individuals between 20-40 years of age and every year for individual above 40 years of age.

The global market for basal cell carcinoma is segmented by type of advance basal cell carcinoma, therapeutic type, end-user, and geography.

Segment by disease indication

  • Locally advanced basal cell carcinoma
  • Metastatic advance basal cell carcinoma

Segment by therapeutic type

  • Topical Medication
    • Imiquimod
    • 5-Fluorouracil(5-FU)
    • Tazarotene
    • Podophyllin 
  • Injectable
    • Interferon Alpha 2b
  • Oral Medication
    • Vismodegib
    • Sonidegib

Segment by Distribution Channel

  • Hospitals
  • Research Institutes
  • Cancer Diagnostic Centers
  • Ambulatory Surgical Centers
  • Retail Pharmacies

The global market for advance basal cell carcinoma is segmented into five key regions viz.  North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. The region of North America leads the market for advanced basal cell carcinoma therapeutics and is closely followed by European region. It is estimated that in coming years more people will get affected by advance basal cell carcinoma in the U.S and the U.K. In recent times the Asia-Pacific region has observed a substantial growth in advance basal cell carcinoma therapeutic market as number of people are getting affected by advance basal cell carcinoma, thus increasing the demand for therapeutics in the region.

The major factors driving the growth of the market for advance basal cell carcinoma are increasing aging population, environmental changes, increased use of immunosuppressant, increased exposure to sunlight, increased demand for new therapeutics and better reimbursement policies. The restraining factor for advance basal cell carcinoma therapeutics market is delay in accessing medical condition, lack of awareness amongst individual and cost of certain therapeutics. As technological advancements are made some therapeutic drugs are being discovered which are in clinical trials and different phases of development would help the therapeutic market for advance basal cell carcinoma to grow.

Key players involved in advance basal cell carcinoma market are F. Hoffmann-La Roche Ltd., Novartis, Genentech Inc., Merck & Co. Inc., Bristol-Myers Squibb Company, Cannabis Science, INC., Curis Inc., Galderma S.A., and Graceway Pharmaceuticals and others

Note : All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Transparency Market Research.

Have query on this report?

Make an Enquiry

Success Stories

Our Clients